Dr. Jyoti Patel on Delaying Whole Brain Radiation for Brain Metastases

Article

Jyoti Patel, MD, of Northwestern University's Feinberg School of Medicine, talks about the subject of delaying whole brain radiation for brain metastases.

Jyoti Patel, MD, of Northwestern University's Feinberg School of Medicine, talks about the subject of delaying whole brain radiation for brain metastases.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with dark curly hair wearing a floral shirt
3 experts in this video
3 experts in this video
Image of a woman with gray hair on a light blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a private infusion bay with a large screen for video calls
2 experts are featured in this series.
Related Content
The FDA granted fast track designation to ZL-1310 to treat patients with extensive-stage small cell lung cancer.

FDA Grants Fast Track Designation to ZL-1310 in Extensive Stage SCLC

Courtney Flaherty
May 20th 2025
Article

The agent is currently being evaluated as both monotherapy and in combination with atezolizumab in patients with extensive stage SCLC in an ongoing, global phase 1 trial.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Graphic reading "FDA Approved" resembling an approval stamp

Telisotuzumab Vedotin-tllv Given Accelerated Approval for NSCLC

Bridget Hoyt
Published: May 14th 2025 | Updated: May 16th 2025
Article

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Anatomical image of a person with a tumor on their lung

First-Line Adagrasib Active in STK11/KRAS G12C–Mutated NSCLC

Jordyn Sava
May 4th 2025
Article

Adagrasib shows early signs of activity and tolerability in patients with STK11/KRAS G12C–mutated non–small cell lung cancer.

Line illustration of a clipboard that says "FDA" with an approval mark in front on a cornflower blue background

A Snapshot of April FDA Approvals in Oncology for Nurses and APPs

Bridget Hoyt
May 1st 2025
Article

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.